Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 15, 2002Blood

Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus–infected patients treated for non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMarcello PersicoUniversity of SalernoFMFedele De MarinoGRGiovanni Di Giacomo Russo

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Persico et al. (2002) studied this question.

synapsesocial.com/papers/6a947faf7779db04076e5dc8https://doi.org/10.1182/blood.v99.2.724
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection1995 · 810 citations
  2. 2Hepatitis C virus infection in patients with non‐Hodgkin's lymphoma1994 · 458 citations
  3. 3Fatal Reactivation of Chronic Hepatitis B Virus Infection Following Withdrawal of Chemotherapy in Lymphoma Patients1989 · 141 citations
  4. 4Lamivudine and Glycyrrhizin for Treatment of Chemotherapy-Induced Hepatitis B Virus (HBV) Hepatitis in a Chronic HBV Carrier with Non-Hodgkin Lymphoma2001 · 34 citations
  5. 5Prevalence of hepatitis B or C virus infections in patients with non‐Hodgkin's lymphoma2001 · 110 citations